Clinical Trial

Silk Bioprotein as a Wound Dressing for Double-Incision Mastectomy

Recruiting
View on ClinicalTrials.gov →
Summary
This study will investigate the utility of Silk bioprotein, an FDA-approved and readily available post-surgical dressing, as a wound dressing for patients undergoing double-incision mastectomy for female-to-male gender affirmation surgery.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-04-03; most recent amendment 2026-06-05.
Status change: Not Yet Recruiting → Recruiting 2025-05-30
Trial Details
NCT Number NCT06921148
Lead Sponsor Indiana University
Conditions Wound Healing
Enrollment 50 participants
Start Date 2025-04-30
Primary Completion 2028-04-30 (estimated)
Study Completion 2028-06-14 (estimated)
Updated on ClinicalTrials.gov 2026-06-09